Literature DB >> 18325622

Impact of the reduction of the prescription charge in Wales on the prescribing of non-sedating antihistamines in primary care.

Teerapon Dhippayom1, Roger Walker.   

Abstract

OBJECTIVE: Determine the impact of the phased reduction of the prescription charge in Wales on prescriptions for non-sedating antihistamines.
METHOD: Prescription items for non-sedating antihistamines dispensed in 22 Local Health Boards (LHBs) in Wales and 15 Primary Care Trusts in the South East of England were analysed between October 2001 and September 2006.
RESULTS: There was an increase in percent change (median (interquartile range [IQR])) in prescription items for non-sedating antihistamines dispensed in Wales in the 24 months after the first reduction of the prescription charge in October 2004 compared to the 24 months prior to this (13.7 [10.9-17.1] vs. 7.3 [5.0-10.7], p<0.001). In the South East of England there was no change over the same periods (4.4 [3.4-7.5] vs. 4.5 [0.8-7.9], p=0.73). In the five least deprived LHBs the percent change in prescriptions for non-sedating antihistamines increased in the 24 months after the reduction of the prescription charge compared to the previous 24 months (14.3 [11.5-19.4] vs. 9.0 [9.1-13.5], p=0.04). In contrast there was no change over the two periods in the five most deprived LHBs (13.1 [10.9-17.5] vs. 9.5 [2.9-10.4], p=0.08].
CONCLUSIONS: The phased reduction of the prescription charge in Wales coincided with an increase in the number of non-sedating antihistamines dispensed in Wales. This was only evident in the least deprived LHBs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325622     DOI: 10.1016/j.healthpol.2008.01.006

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  1 in total

1.  Impact of abolishing prescription fees in Scotland on hospital admissions and prescribed medicines: an interrupted time series evaluation.

Authors:  Andrew James Williams; William Henley; John Frank
Journal:  BMJ Open       Date:  2018-12-18       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.